Considering haploinsufficiency of Nav1.5 as a key mechanism in Brugada syndrome, patient-derived iPS-CM offer a unique advantage since the transcriptional activity of these cells occurs free of experimental artifacts inherent to heterologous expression systems. The gene discussed is SCN5A; the disease is Brugada syndrome.